First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 3.8 USD -1.81% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

FATE Price Targets Summary
Fate Therapeutics Inc

Wall Street analysts forecast FATE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FATE is 7.96 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

FATE Lowest Forecast
Wall Street Target
5.05 USD
33% Upside
FATE Average Forecast
Wall Street Target
7.96 USD
109% Upside
FATE Highest Forecast
Wall Street Target
12.6 USD
232% Upside
Lowest
Price Target
5.05 USD
33% Upside
Average
Price Target
7.96 USD
109% Upside
Highest
Price Target
12.6 USD
232% Upside
Fate Therapeutics Inc Competitors:
Price Targets
K
2162
KeyMed Biosciences Inc
80% Upside
S
002880
Shenzhen Weiguang Biological Products Co Ltd
48% Upside
A
397030
AprilBio Co Ltd
83% Upside
OPK
OPKO Health Inc
244% Upside
K
2162
KeyMed Biosciences Inc
80% Upside
S
002880
Shenzhen Weiguang Biological Products Co Ltd
48% Upside
A
397030
AprilBio Co Ltd
83% Upside
OPK
OPKO Health Inc
244% Upside
KRRO
Korro Bio Inc
111% Upside
4978
ReproCell Inc
100% Upside
A
AELIS
Aelis Farma SA
69% Upside
QNCX
Quince Therapeutics Inc
183% Upside

Revenue
Forecast

Revenue Estimate
Fate Therapeutics Inc

For the last 8 years the compound annual growth rate for Fate Therapeutics Inc's revenue is 50%. The projected CAGR for the next 3 years is -56%.

50%
Past Growth
-56%
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Fate Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Fate Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss
What are analyst estimates?

See Also

Summary
FATE intrinsic value, competitors valuation, and company profile.
DCF Valuation
FATE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FATE stock valuation using valuation multiples.
Wall Street Estimates
FATE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FATE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FATE's stock price target?
Price Target
7.96 USD

According to Wall Street analysts, the average 1-year price target for FATE is 7.96 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

What is Fate Therapeutics Inc's Revenue forecast?
Projected CAGR
-56%

For the last 8 years the compound annual growth rate for Fate Therapeutics Inc's revenue is 50%. The projected CAGR for the next 3 years is -56%.

ALPHA SPREAD
Join more than 132,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.